Acute Respiratory Distress Syndrome - Pipeline Review, H1 2016

Transcription

1 Report Information More information from: eguyreports.com/reports/ Acute Respiratory Distress Syndrome - Pipeline Review, H Report / Search Code: WGR Publish Date: 29 February, 2016 Price 1-user PDF : $ Site PDF : $ Enterprise PDF : $ Description: Acute Res piratory Dis tres s Syndrome - Pipeline Review, H Summary Global Markets Direct s, Acute Res piratory Dis tres s Syndrome - Pipeline Review, H1 2016, provides an overview of the Acute Res piratory Dis tres s Syndrome pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Acute Res piratory Dis tres s Syndrome, complete with analys is by stage of development, drug target, mechanism of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics, its complete res earch and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Res piratory Dis tres s Syndrome and features dormant and dis continued projects. Global Markets Direct s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications. The report is built us ing data and information s ourced from Global Markets Direct s proprietary databas es, company/univers ity webs ites, clinical trial regis tries, conferences, SEC filings, investor presentations and featured press releases from company/univers ity s ites and indus try-s pecific third party s ources. Drug profiles featured in the report undergoes periodic review following a s tringent s et of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome - The report reviews pipeline therapeutics for Acute Res piratory Dis tres s Syndrome by companies and univers ities/res earch ins titutes bas ed on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features des criptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R& D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acute Res piratory Dis tres s Syndrome therapeutics and enlists all their major and minor projects - The report assesses Acute Respiratory Distress Syndrome therapeutics based on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Acute Res piratory Dis tres s Syndrome Reasons to buy - Gain s trategically s ignificant competitor information, analys is, and ins ights to formulate effective R& D strategies - Identify emerging players with potentially s trong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Acute Respiratory Distress Syndrome - Identify potential new clients or partners in the target demographic

2 - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it s mos t promising pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents: Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acute Respiratory Distress Syndrome Overview 9 Therapeutics Development 10 Pipeline Products for Acute Respiratory Distress Syndrome - Overview 10 Pipeline Products for Acute Res piratory Dis tres s Syndrome - Comparative Analys is 11 Acute Res piratory Dis tres s Syndrome - Therapeutics under Development by Companies 12 Acute Res piratory Dis tres s Syndrome - Therapeutics under Inves tigation by Universities/Institutes 13 Acute Respiratory Distress Syndrome - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Acute Res piratory Dis tres s Syndrome - Products under Development by Companies 17 Acute Res piratory Dis tres s Syndrome - Products under Inves tigation by Universities/Institutes 18 Acute Res piratory Dis tres s Syndrome - Companies Involved in Therapeutics Development 19 Altor BioScience Corporation 19 Athersys, Inc. 20 Faron Pharmaceuticals Oy 21 FirstString Research, Inc. 22 GlaxoSmithKline Plc 23 Histocell S.L. 24 Phylogica Limited 25 Serendex Pharmaceuticals A/S 26 Silence Therapeutics Plc 27 Therabron Therapeutics, Inc. 28 Acute Respiratory Distress Syndrome - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 ALT Drug Profile 38 Product Description 38 Mechanism of Action 38 R& D Progress 38 BIO Drug Profile 40 Product Description 40 Mechanism of Action 40 R& D Progress 40 CG Drug Profile 41 Product Description 41 Mechanism of Action 41 R& D Progress 41 Cyndacel-M - Drug Profile 42 Product Description 42 Mechanism of Action 42 R& D Progress 42 GSK Drug Profile 44 Product Description 44 Mechanism of Action 44 R& D Progress 44 GSK Drug Profile 45 Product Description 45 Mechanism of Action 45

3 R& D Progress 45 interferon beta-1a - Drug Profile 46 Product Description 46 Mechanism of Action 46 R& D Progress 46 molgramostim - Drug Profile 48 Product Description 48 Mechanism of Action 48 R& D Progress 48 Monoclonal Antibodies to Inhibit upa for Infectious Dis eas e and Res piratory Disorders - Drug Profile 52 Product Description 52 Mechanism of Action 52 R& D Progress 52 Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertens ion - Drug Profile 53 Product Description 53 Mechanism of Action 53 R& D Progress 53 PF Drug Profile 54 Product Description 54 Mechanism of Action 54 R& D Progress 54 PYC-35 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R& D Progress 58 PYC-36 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R& D Progress 59 PYC-38 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R& D Progress 60 PYC-98 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R& D Progress 61 Recombinant Proteins for Acute Lung Injury and Acute Res piratory Dis tres s Syndrome - Drug Profile 62 Product Description 62 Mechanism of Action 62 R& D Progress 62 S Drug Profile 63 Product Description 63 Mechanism of Action 63 R& D Progress 63 SAN Drug Profile 64 Product Description 64 Mechanism of Action 64 R& D Progress 64 Small Molecule to Inhibit MMP and Cytokine for Immunology, Res piratory and Musculoskeletal Disorders - Drug Profile 65 Product Description 65 Mechanism of Action 65 R& D Progress 65 Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile 66 Product Description 66 Mechanism of Action 66 R& D Progress 66 Stromal Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile 67 Product Description 67 Mechanism of Action 67 R& D Progress 67 Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 68 Product Description 68 Mechanism of Action 68 R& D Progress 68 Acute Respiratory Distress Syndrome - Recent Pipeline Updates 69 Acute Respiratory Distress Syndrome - Dormant Projects 81 Acute Respiratory Distress Syndrome - Discontinued Products 82 Acute Respiratory Distress Syndrome - Product Development Milestones 83 Featured News & Press Releases 83 Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS 83 Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for

4 treatment of acute respiratory distress syndrome 83 Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP 84 Aug 09, 2015: Serendex to initiate first phase II clinical trial 85 Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November 85 May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced 86 May 20, 2015: Novozymes Biopharma enables s table formulation of Serendex Pharmaceutical s inhalable biological drug for treatment of s evere pulmonary diseases 86 May 10, 2015: Positive topline data from Serendex phase I clinical trial 87 Feb 27, 2015: Serendex submits phase I application 88 Feb 13, 2015: Serendex partners up with leading German lung center 88 Appendix 90 Methodology 90 Coverage 90 Secondary Research 90 Primary Research 90 Expert Panel Validation 90 Contact Us 90 Dis claimer 91 List of Tables Number of Products under Development for Acute Res piratory Dis tres s Syndrome, H Number of Products under Development for Acute Res piratory Dis tres s Syndrome - Comparative Analysis, H Number of Products under Development by Companies, H Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Late Stage Development, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Development, H Products under Development by Companies, H Products under Investigation by Universities/Institutes, H Acute Res piratory Dis tres s Syndrome - Pipeline by Altor BioScience Corporation, H Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H Acute Res piratory Dis tres s Syndrome - Pipeline by Faron Pharmaceuticals Oy, H Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H Acute Respiratory Distress Syndrome - Pipeline by Histocell S.L., H Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H Acute Res piratory Dis tres s Syndrome - Pipeline by Serendex Pharmaceuticals A/S, H Acute Res piratory Dis tres s Syndrome - Pipeline by Silence Therapeutics Plc, H Acute Res piratory Dis tres s Syndrome - Pipeline by Therabron Therapeutics, Inc., H Assessment by Monotherapy Products, H Number of Products by Stage and Target, H Number of Products by Stage and Mechanism of Action, H Number of Products by Stage and Route of Administration, H Number of Products by Stage and Molecule Type, H Acute Res piratory Dis tres s Syndrome Therapeutics - Recent Pipeline Updates, H Acute Respiratory Distress Syndrome - Dormant Projects, H Acute Respiratory Distress Syndrome - Discontinued Products, H List of Figures Number of Products under Development for Acute Res piratory Dis tres s Syndrome, H Number of Products under Development for Acute Res piratory Dis tres s Syndrome - Comparative Analysis, H Number of Products under Development by Companies, H Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Products, H Assessment by Monotherapy Products, H Number of Products by Top 10 Targets, H Number of Products by Stage and Top 10 Targets, H Number of Products by Top 10 Mechanism of Actions, H Number of Products by Stage and Top 10 Mechanism of Actions, H Number of Products by Routes of Administration, H Number of Products by Stage and Routes of Administration, H Number of Products by Molecule Types, H Number of Products by Stage and Molecule Types, H

5 wiseguyreports.com / Phone (US) (UK)